Avantor to Feature New Excipients and Packaging Options at CPhI Worldwide 2015

Published on: 

Avantor’s featured products at this year’s CPhI include the new high-purity, low-endotoxin sugars, the new Direct Dispense proprietary packaging platform, and the J.T.Baker Bakerbond process chromatography media.

Avantor Performance Materials announced that it has expanded its manufacturing capabilities to purify bioexcipients and will be unveiling its new line of high-purity, low-endotoxin (HPLE) sugars at CPhI Worldwide 2015, taking place in Madrid, Spain, from October 13–15. These sugars, produced using proprietary purification technology, have endotoxin levels below regulatory requirements and contain low impurity levels, thereby, enhancing patient safety by reducing the potential for adverse reactions. The HPLE sugars are said to increase the efficacy of APIs while improving cell culture yield, according to Avantor. The company’s representatives will be sharing information about this new line of excipients at the Advance Biopharmaceuticals exhibit, located in booth 7B40.

Avantor will also be showcasing its innovative ready-to-use packaging options. The new J.T.Baker Direct Dispense packaging platform is designed to deliver pre-weighed salt buffers and cell culture ingredients to help manufacturers streamline biopharmaceutical production. It is available for a range of J.T.Baker dry powder products in quantities from 250g to 15kg, and is compatible with near-IR identification testing, reducing the need for sampling, material handling and the risk of cross-contamination.

Visitors can also learn more about other product offerings from Avantor, such as the company’s process chromatography media and cGMP-manufactured process salts, sugars, and excipients.

Exhibitor showcase presentation

As part of the CPhI exhibitor showcase program, Avantor experts Nandu Deorkar, PhD, vice-president of R&D, and William Hesselink, application project manager R&D for Pharmaceuticals, will deliver a presentation on Improving the Robustness of Biopharmaceutical Manufacturing Processes by Controlling Raw Material Variability.


Deorkar and Hesselink will discuss the emerging regulatory requirements in biopharmaceutical manufacturing and illustrate critical quality attributes of various raw materials and excipients, along with approaches to control variability and thereby improve biopharmaceutical manufacturing outcomes.

The presentation will take place Tuesday, October 13, at 2:30 p.m. at the CPhI Exhibitor Showcase location: Hall 12, Stand Nr. 12F40.

Source: Avantor, Booth 7B40